S1PR1 and multiple sclerosis: Fingolimod, a first-generation S1PR modulator, has been approved by the FDA for treating multiple sclerosis, but the drug has poor target selectivity and widely acts on S1PR1-5; accordingly, the side effects are relatively large, mainly due to the drug binding to S1P receptors rather than S1PR1 (138–140).